טוען...
PD-L1 inhibitors in the pipeline: Promise and progress
Checkpoint inhibitors have improved survival for patients with melanoma, non-small-cell lung cancer (NSCLC), bladder, head and neck and other cancers. Antibodies against PD-L1, including atezolizumab, avelumab and durvalumab, are also being developed and have been approved for various cancers. Compa...
שמור ב:
| הוצא לאור ב: | Oncoimmunology |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Taylor & Francis
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5739559/ https://ncbi.nlm.nih.gov/pubmed/29296516 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1365209 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|